Immatics (IMTX) Other Non-Current Liabilities (2019 - 2025)
Immatics (IMTX) reported Other Non-Current Liabilities of $7.8 million for Q3 2025, down 51.78% on a YoY basis from $16.2 million in Q3 2024, and up 5488.71% sequentially from $139900.6 in Q1 2025.
Immatics (IMTX) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Other Non-Current Liabilities data on file, last reported at $7.8 million in Q3 2025.
- For the quarter ending Q3 2025, Other Non-Current Liabilities fell 51.78% year-over-year to $7.8 million; the trailing twelve-month figure through Sep 2025 stood at $7.8 million (down 51.78% YoY), and the FY2024 full-year result was $1.9 million, up 43174.82% from the prior year.
- Other Non-Current Liabilities advanced to $7.8 million in Q3 2025, from $139900.6 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $19.5 million in Q1 2024 to a low of $4303.8 in Q4 2023.
- A 5-year average of $3.1 million and a median of $77790.0 in 2021 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities jumped 74378.01% in 2024 and sank 99.28% in 2025, its largest moves.
- Tracing IMTX's Other Non-Current Liabilities over 5 years: stood at $77790.0 in 2021, then tumbled by 44.92% to $42850.4 in 2022, then slumped by 89.96% to $4303.8 in 2023, then surged by 42854.77% to $1.8 million in 2024, then soared by 322.93% to $7.8 million in 2025.
- Business Quant data shows IMTX's Other Non-Current Liabilities at $7.8 million in Q3 2025, $139900.6 in Q1 2025, and $1.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immatics | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.82 Mn |
| Mar 31, 2025 | 139,900.63 |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 16.22 Mn |
| Mar 31, 2024 | 19.50 Mn |
| Dec 31, 2023 | 4,303.76 |
| Sep 30, 2023 | 21,771.81 |
| Jun 30, 2023 | 28,312.03 |
| Mar 31, 2023 | 35,420.28 |
| Dec 31, 2022 | 42,850.39 |
| Sep 30, 2022 | 55,455.09 |
| Jun 30, 2022 | 62,956.34 |
| Mar 31, 2022 | 70,707.28 |
| Dec 31, 2021 | 77,790.02 |
| Sep 30, 2021 | 3.63 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | 1.17 Mn |
| Dec 31, 2020 | 60,806.78 |
| Sep 30, 2020 | 2.38 Mn |
| Jun 30, 2020 | 1.59 Mn |